Novartis

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population; PSMAddition ...